Search research articles
Contact Us
Filters
Showing results (141-150 of 205) with videos related to
Page
of 21
Sort By:
The Journal of Clinical Investigation
|
August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Andrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
European Urology
|
July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology
|
February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Nature Communications
|
November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
Jeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
Nature Communications
|
December 13, 2025
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling
Michael S Sturdivant, Andrew S Truong, Mi Zhou, et al.
The Journal of Urology
|
May 8, 2024
Decisional Conflict Among Patients Newly Diagnosed With Clinical T1 Renal Masses: A Prospective Study
Amir Feinberg, Kathryn H Gessner, Allison M Deal, et al.
Urologic Oncology
|
July 1, 2015
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings
Tracy L Rose, Allison M Deal, Ethan Basch, et al.
European Urology
|
August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Cancer Research Communications
|
August 8, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features
N Ari Wijetunga, Kathryn H Gessner, Krishna Kanchi, et al.
Journal for Immunotherapy of Cancer
|
October 1, 2017
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 205) with videos related to
Sort By:
Page
of 21
The Journal of Clinical Investigation
|
August 16, 2021
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Andrew S Truong, Mi Zhou, Bhavani Krishnan, et al.
European Urology
|
July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology
|
February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Nature Communications
|
November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
Jeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
Nature Communications
|
December 13, 2025
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling
Michael S Sturdivant, Andrew S Truong, Mi Zhou, et al.
The Journal of Urology
|
May 8, 2024
Decisional Conflict Among Patients Newly Diagnosed With Clinical T1 Renal Masses: A Prospective Study
Amir Feinberg, Kathryn H Gessner, Allison M Deal, et al.
Urologic Oncology
|
July 1, 2015
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings
Tracy L Rose, Allison M Deal, Ethan Basch, et al.
European Urology
|
August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Cancer Research Communications
|
August 8, 2024
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features
N Ari Wijetunga, Kathryn H Gessner, Krishna Kanchi, et al.
Journal for Immunotherapy of Cancer
|
October 1, 2017
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, et al.
Page
of 21